Published in Eur J Clin Microbiol Infect Dis on April 27, 2004
Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol (2007) 0.80
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Chronic hepatitis B. Hepatology (2001) 5.90
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med (1986) 4.51
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet (2000) 4.29
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS (1997) 2.88
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 2.54
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med (2002) 2.20
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology (1998) 2.12
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat (2003) 1.97
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet (1997) 1.97
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS (2001) 1.92
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis (2003) 1.89
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (2002) 1.85
Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis (2003) 1.80
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology (2000) 1.76
Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis (1991) 1.75
The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis (1991) 1.69
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Vaccines to prevent viral hepatitis. N Engl J Med (1997) 1.58
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52
Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med (1988) 1.47
Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr (2000) 1.46
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect (1998) 1.37
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology (1999) 1.32
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet (1997) 1.30
Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J (Clin Res Ed) (1987) 1.28
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine (2000) 1.23
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet (1995) 1.22
Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis (1999) 1.22
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev (2002) 1.18
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses (2001) 1.17
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS (2003) 1.15
The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology (1987) 1.14
The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis (1989) 1.13
Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr (2002) 1.07
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology (2002) 1.06
Severe hepatitis in three AIDS patients treated with indinavir. Lancet (1997) 1.04
Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS (1992) 1.04
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother (2002) 1.03
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis (2002) 1.03
Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med (1989) 1.02
Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med (1986) 1.01
Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology (1987) 1.01
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS (2002) 1.01
Case-control study of sexually transmitted diseases as cofactors for HIV-1 transmission. Int J STD AIDS (1996) 0.99
Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med (1992) 0.99
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol (1999) 0.98
Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis (1997) 0.97
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis (1999) 0.96
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis (2001) 0.96
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother (2000) 0.96
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS (2003) 0.96
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS (2003) 0.95
Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health (1990) 0.92
Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol (1990) 0.92
Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS (1994) 0.92
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med (2003) 0.92
Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol (1987) 0.91
Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol (2002) 0.89
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ (1989) 0.88
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat (1999) 0.88
Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med (1996) 0.87
Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA (1989) 0.87
Is the combination of hepatitis and indinavir potentially dangerous? AIDS (1998) 0.87
Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology (1990) 0.86
Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 0.85
BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med (2003) 0.85
Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2000) 0.84
Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol (1988) 0.84
Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type-1 and hepatitis B viral replication. Hepatology (1992) 0.83
The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol (1996) 0.83
Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology (1992) 0.82
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother (2002) 0.81
Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol (1991) 0.79
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology (2000) 0.76
Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology (1995) 0.76
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med (2003) 1.94
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Med (2010) 1.45
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med (2010) 1.23
Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol (2001) 1.16
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med (2009) 1.14
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther (2012) 1.10
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med (2008) 1.09
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat (2009) 1.07
Editorial: NAFLD in HIV infection--call for action. Aliment Pharmacol Ther (2015) 1.06
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology (2011) 1.05
Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1. J Virol (2001) 1.03
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med (2011) 1.03
British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med (2010) 0.97
The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection. J Infect (1996) 0.93
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther (2014) 0.92
Phenotypic analysis of peripheral blood gammadelta T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo. Virology (2003) 0.87
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK. HIV Med (2011) 0.78
The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. HIV Med (2013) 0.78
Brain biopsy in AIDS patients: what are the indications? Br J Neurosurg (1998) 0.77
Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS. Int J STD AIDS (1998) 0.76
Mycoplasma infection and Kawasaki disease. Arch Dis Child (1996) 0.75
Changing trends in cytomegalovirus retinitis with highly active anti-retroviral therapy (HAART) Eye (Lond) (1999) 0.75
The order in Kerry. Caritas (1984) 0.75
Late diagnosis of HIV: could this be avoided? Scott Med J (2011) 0.75
Transient neutropenia and thrombocytopenia due to benoxaprofen. Lancet (1982) 0.75
Features and outcome of Pneumocystis carinii pneumonia according to risk category for HIV infection. Scand J Infect Dis (1997) 0.75
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. AIDS (2000) 0.75